Aclidinium Pharmacology and Mechanism of Action
Aclidinium is a specialized medication designed to improve respiratory function by acting as a long-acting, reversible antagonist at muscarinic receptors—proteins that transmit signals in the parasympathetic nervous system. By blocking these receptors, Aclidinium helps manage airflow in patients with respiratory conditions.
Mechanism of Action
Aclidinium demonstrates a similar affinity for all five subtypes of muscarinic receptors. However, its clinical effectiveness is driven by its specific dissociation half-life—the time it takes for the drug to detach from the receptor. Specifically, its dissociation half-life from the M3 subtype is 29.2 hours, which is six times longer than its dissociation from the M2 subtype.
The drug's primary therapeutic benefit occurs at the M3 receptors located in the smooth muscle of the bronchioles (the smallest air passages in the lungs). By inhibiting these receptors, Aclidinium reduces muscle contraction, thereby opening the airways and improving airflow. Conversely, its affinity for M2 receptors is the primary driver of potential adverse effects related to the heart.
[ไม่มีภาพประกอบ]
Comparative Dissociation Half-Lives
To understand Aclidinium's duration of action, it is helpful to compare its M3 dissociation half-life with other related medications:
- Ipratropium: 0.47 hours
- Aclidinium: 29.2 hours
- Tiotropium: 62.2 hours
Pharmacokinetics
When administered via inhalation, approximately 30% of Aclidinium is deposited directly into the lungs, where its effects persist for more than 24 hours. Following deposition, the drug is absorbed into the bloodstream. In healthy individuals, peak blood plasma concentrations are reached within five minutes, while in patients with Chronic Obstructive Pulmonary Disease (COPD), this peak occurs between 10 to 15 minutes.
The body rapidly processes the substance through hydrolysis—a chemical breakdown involving water. This process is both non-enzymatic and enzymatic, with the latter primarily facilitated by butyrylcholinesterase. Because of this rapid breakdown, less than 5% of the inhaled dose remains unchanged in the plasma.
The hydrolysis process results in two metabolites: a carboxylic acid and an alcohol. The acid metabolite has a plasma protein binding rate of 87%, while the alcohol metabolite binds at 15%. These metabolites are eliminated from the body, with 65% excreted in the urine and 33% in the faeces. The overall elimination half-life is two to three hours, and only 0.1% of the total dose is excreted as unchanged Aclidinium.
Key Facts
- Primary Target: M3 muscarinic receptors in the bronchioles.
- Duration: Lung action lasts over 24 hours.
- M3 Dissociation Half-Life: 29.2 hours.
- Absorption: 30% of the inhaled dose reaches the lungs.
- Metabolism: Rapidly hydrolyzed by butyrylcholinesterase and non-enzymatic processes.
- Excretion: Primarily via urine (65%) and faeces (33%).
| Parameter | Value / Detail |
|---|---|
| M3 Dissociation Half-Life | 29.2 hours |
| Lung Deposition Rate | ~30% |
| Plasma Peak (Healthy) | 5 minutes |
| Plasma Peak (COPD) | 10–15 minutes |
| Elimination Half-Life | 2–3 hours |
| Unchanged Drug Excretion | 0.1% |
Frequently Asked Questions
How does Aclidinium improve breathing?
Aclidinium blocks M3 muscarinic receptors in the smooth muscles of the bronchioles, which reduces muscle contraction and allows the airways to open, improving overall airflow.
What is the difference between Aclidinium and Tiotropium in terms of duration?
While both are long-acting, Aclidinium has an M3 dissociation half-life of 29.2 hours, which is shorter than Tiotropium's 62.2 hours, but significantly longer than Ipratropium's 0.47 hours.
Why does Aclidinium cause heart-related side effects?
Adverse effects at the heart are primarily attributed to the drug's affinity for the M2 muscarinic receptor subtype.
How is Aclidinium removed from the body?
The drug is rapidly hydrolyzed into a carboxylic acid and an alcohol. These metabolites are then excreted, with 65% leaving through urine and 33% through faeces.
How quickly does the drug enter the bloodstream?
Peak plasma concentrations are reached within 5 minutes for healthy individuals and between 10 to 15 minutes for those with COPD.